Literature DB >> 25076333

Elderly patients with pancreatic cancer.

Andromachi S Kougioumtzopoulou1, Kostas N Syrigos, Muhammad Wasif Saif.   

Abstract

Pancreatic cancer marked significant increase of incidence during the last decades in the elderly population. Despite the certain increase of incidence there are no international guidelines for elderly patients who are suffering from pancreatic cancer. During the ASCO Annual Meeting 2014, two abstracts focusing on elderly patients suffering from different histological types of pancreatic cancer were presented. The first retrospective study (Abstract #4119) showed the benefit of the systemic treatment on overall survival for elderly patients with stage IV pancreatic adenocarcinoma. The second retrospective study (Abstract #4112) demonstrates the positive effect of somatostatin analogue (octreotide-LAR) treatment on overall survival for elderly patients with neuroendocrine pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25076333     DOI: 10.6092/1590-8577/2682

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  3 in total

1.  Impact of Comorbidity and Age on Determinants Therapeutic Strategies in Advanced Pancreatic Head Cancer Patients With Obstructive Jaundices.

Authors:  Yu-Guang Chen; Hsueh-Hsing Pan; Ming-Shen Dai; Chin Lin; Chieh-Sheng Lu; Sui-Lung Su; Ping-Ying Chang; Tzu-Chuan Huang; Jia-Hong Chen; Yi-Ying Wu; Yeu-Chin Chen; Ching Liang Ho
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

2.  Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma.

Authors:  Wei Li; Yaomei Wang; Daniel B Kellner; Linping Xu; Ling Mai
Journal:  Cent Eur J Immunol       Date:  2015-08-03       Impact factor: 2.085

3.  A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer.

Authors:  Omar Abdel-Rahman; Yuan Xu; Patricia A Tang; Richard M Lee-Ying; Winson Y Cheung
Journal:  Cancer Med       Date:  2018-10-30       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.